Financing led by Viking Global Investors alongside a syndicate of venture philanthropy investors with deep expertise in epidermolysis bullosa

由 Viking Global Investors 领衔，联合一批在表皮松解性大疱症领域拥有深厚专业知识的风险慈善投资者组成的银团共同提供融资。

Proceeds to support scale-up manufacturing, IND-enabling development of NvA-021, and advance the program through an initial clinical proof-of-concept study

资金将用于支持规模化生产、推进NvA-021的临床试验申请（IND） enabling 开发，并通过初步的临床概念验证研究推动该项目的进展。

BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nova Anchora, a biotechnology company developing a corrective topical protein therapy for dystrophic epidermolysis bullosa (DEB), today announced a $23 million equity financing led by Viking Global Investors, with participation from DEBRA Research gGmbH, EB Research Partnership (EBRP), the EB Medical Research Foundation (EBMRF), and Cure EB.

波士顿，2026年11月5日（环球电讯社）——致力于开发营养不良性大疱性表皮松解症（DEB）矫正型外用蛋白疗法的生物技术公司Nova Anchora今日宣布完成一轮由Viking Global Investors领投的2300万美元股权融资，DEBRA Research gGmbH、EB研究合作伙伴关系（EBRP）、EB医学研究基金会（EBMRF）以及Cure EB参与投资。

The round includes an initial tranche and additional capital committed subject to the achievement of specified development milestones..

本轮融资包括初始批次资金，以及以达成特定开发里程碑为条件的追加承诺资本。

The financing is intended to support the advancement of Nova Anchora’s lead candidate, NvA-021, through an initial clinical proof-of-concept study. Building on progress in manufacturing and preclinical development, the company plans to use the proceeds to complete investigational new drug (IND)-enabling studies, manufacture clinical supply, submit an IND application to the FDA, and conduct the clinical study..

本次融资旨在支持Nova Anchora的核心候选药物NvA-021通过初步临床概念验证研究。基于在生产和临床前开发方面取得的进展，公司计划将所得资金用于完成支持新药临床试验申请（IND）的研究、生产临床供应物资、向美国食品药品监督管理局（FDA）提交IND申请，并开展临床研究。

DEB is a rare genetic disease in which type VII collagen (C7), a protein essential to keeping the skin’s protective layer intact, is absent or does not function properly. The resulting fragility means even minor skin friction can result in blistering and open wounds. Despite advances in treatment, significant unmet needs remain, including options that enable patients to treat more of their wounds and fit more easily into routine care at home..

营养不良性大疱性表皮松解症（DEB）是一种罕见的遗传性疾病，患者体内缺失或功能异常的VII型胶原（C7）是维持皮肤保护层完整性的关键蛋白。由此导致的皮肤脆弱性意味着即使是轻微的摩擦也可能引发水疱和开放性伤口。尽管治疗手段已取得进展，但仍存在显著的未满足需求，包括能够为患者提供更多伤口治疗选择、并更易于融入居家常规护理的方案。

NvA-021 is an investigational topical gel containing recombinant human C7, designed for application to wounds during routine bandage changes. The therapy is intended to supply functional C7 directly to the affected skin and help restore the anchoring structures that connect the epidermis to the underlying dermis.

NvA-021 是一种在研的局部用凝胶，含有重组人 VII 型胶原（C7），旨在常规更换敷料时涂抹于伤口。该疗法旨在直接向受损皮肤提供功能性 C7，并帮助恢复连接表皮与下方真皮的结构。

NvA-021 is being developed for storage at home and application by patients or caregivers during routine bandage changes..

NvA-021 正在开发中，旨在供患者或护理人员在常规更换敷料时进行家庭储存和使用。

“Our goal is to make a meaningful difference in the lives of people with DEB,” said Jason Bhardwaj, co-founder and Chief Executive Officer of Nova Anchora. “This financing supports a substantial next phase of development, including scale-up manufacturing, IND-enabling studies, and advancing NvA-021 through an initial clinical proof-of-concept study.”.

“我们的目标是为营养不良性大疱性表皮松解症（DEB）患者的生活带来有意义的改变，”Nova Anchora 联合创始人兼首席执行官 Jason Bhardwaj 表示。“这笔融资将支持下一阶段的大规模开发工作，包括扩大生产规模、开展支持新药临床试验申请（IND）的研究，以及通过初步的概念验证临床研究推进 NvA-021 的研发。”

“Recent advances have changed what we can offer people living with DEB, but patients still face a substantial burden of wounds and daily care,” said Peter Marinkovich, M.D., co-founder and Chair of the Scientific Advisory Board of Nova Anchora and Associate Professor of Dermatology at Stanford University.

“最近的进展改变了我们为营养不良性大疱性表皮松解症（DEB）患者提供的治疗方案，但患者仍然面临着沉重的伤口负担和日常护理压力。”斯坦福大学皮肤科副教授、Nova Anchora 联合创始人兼科学顾问委员会主席彼得·马林科维奇博士表示。

“The extent of disease burden and the challenges of clinical management differ from patient to patient and evolve over time. Expanding our treatment options is essential to meeting those needs and building on the progress already achieved.”.

“疾病负担的程度以及临床管理的挑战因患者而异，并随时间推移而演变。扩大我们的治疗选择对于满足这些需求并在已取得进展的基础上进一步发展至关重要。”

“Seeing science that we supported years ago now nearing clinical stages of development is incredibly meaningful for the EB community,” said Michael Hund, CEO of EBRP, the initial philanthropic funder of the underlying research at Stanford University. “For families living with EB, the need for additional treatment options remains urgent.

“看到我们多年前支持的科学研究如今已接近临床开发阶段，这对大疱性表皮松解症（EB）社群而言意义非凡，”斯坦福大学基础研究的初始慈善资助方EBRP的首席执行官迈克尔·亨德表示。“对于深受EB困扰的家庭来说，对更多治疗选择的需求依然迫切。

We’re proud to support the Nova Anchora team as they take the important steps from laboratory to patient treatment.”.

“我们自豪地支持 Nova Anchora 团队，助力他们迈出从实验室到患者治疗的关键步伐。”

“At DEBRA Research, we bring drug-development experience and deep relationships across the EB community to the companies we support,” said Martin Steiner, Ph.D., Managing Director of DEBRA Research. “Nova Anchora’s scientific approach and the team’s progress give us confidence in its potential to address important gaps in DEB treatment.

“在DEBRA研究中，我们将药物开发经验和与EB社区的深厚关系带给我们的支持公司。”DEBRA研究执行董事Martin Steiner博士说。“Nova Anchora的科学方法及其团队的进展使我们有信心其具有填补DEB治疗中重要空白的潜力。”

We are excited to continue our investment in the company as it advances toward clinical studies.”.

我们很高兴随着公司推进临床研究，继续对其进行投资。

Nova Anchora has received pre-IND feedback from the U.S. Food and Drug Administration. Its C7 therapeutic program has also received FDA Orphan Drug and Rare Pediatric Disease designations. NvA-021 remains investigational, and its safety and efficacy have not been established.

Nova Anchora 已收到美国食品药品监督管理局（FDA）的 IND 前反馈。其 C7 治疗项目也已获得 FDA 的孤儿药和罕见儿科疾病认定。NvA-021 仍处于研究阶段，其安全性和有效性尚未确立。

About Nova Anchora

关于 Nova Anchora

Nova Anchora is a biotechnology company developing a corrective topical protein therapy for dystrophic epidermolysis bullosa (DEB), a severe rare genetic skin disease. Co-founded by Jason Bhardwaj and Dr. Peter Marinkovich, the company is advancing NvA-021, an investigational recombinant collagen VII gel designed for application during routine wound care.

Nova Anchora 是一家生物技术公司，正在开发一种用于纠正营养不良型大疱性表皮松解症（DEB）的局部蛋白疗法。DEB 是一种严重的罕见遗传性皮肤病。该公司由 Jason Bhardwaj 和 Peter Marinkovich 博士联合创立，目前正推进 NvA-021 的研发，这是一种研究性重组 VII 型胶原凝胶，旨在常规伤口护理期间使用。

Built on technology licensed from Stanford University, Nova Anchora’s mission is to improve the lives of people affected by DEB. For more information, please visit .

Nova Anchora 基于斯坦福大学授权的技术，其使命是改善营养不良性大疱性表皮松解症（DEB）患者的生活。如需更多信息，请访问。

www.novaanchora.com

www.novaanchora.com

.

。

About Viking Global Investors

关于维京全球投资者

Founded in 1999, Viking Global Investors (“Viking”) is a global investment firm with a long-term, fundamental, research-intensive approach to investing. Viking manages more than $56 billion of capital across public and private investments. Viking has offices in Stamford, New York, London, and San Francisco, and is registered as an investment adviser with the U.S.

维京全球投资者（“Viking”）成立于1999年，是一家全球投资公司，秉持长期、基本面导向且深入研究的投资理念。Viking管理的资本规模超过560亿美元，涵盖公开市场和私募投资。Viking在斯塔姆福德、纽约、伦敦和旧金山设有办公室，并在美国注册为投资顾问。

Securities and Exchange Commission. For more information, please visit .

证券交易委员会。欲了解更多信息，请访问。

www.vikingglobal.com

www.vikingglobal.com

.

。

Contact

联系

Nova Anchora, LLC

新星锚点有限责任公司

admin@novaanchora.com

admin@novaanchora.com